Business Wire

CA-OPENGATE-CAPITAL

14.6.2019 09:02:10 CEST | Business Wire | Press release

Share
OpenGate Capital Sells Omniplast BV to Consortium of Investors

OpenGate Capital , a global private equity firm, announced today that it has sold Omniplast BV (“Omniplast”) to a group of European investors composed of Reedcapital, Luigi M. Chiaraviglio, and Swiss Merchant Corporation. Omniplast was acquired by OpenGate in 2015 through the firm’s original, pre-fund investment in Ivy Group. Financial terms were not disclosed.

Andrew Nikou, OpenGate Capital’s founder and CEO commented, “We believe that Omniplast stands for global innovation in the fields of piping and fitting systems. I am incredibly proud of the efforts of OpenGate’s European team in the four years since acquiring Omniplast and have now fulfilled our mandate to exit the business at an ideal time. I wish the entire team at Omniplast an abundance of success under their new owners’ stewardship.”

The team at OpenGate Capital responsible for this investment and realization included: Julien Lagrèze, Partner; Sebastien Kiekert Le Moult, Partner; Marc Veillas, Managing Director; and Jonny Leppin, Senior Vice President.

Renaud Delaage, Partner at Reedcapital said, “Omniplast has a tremendous management team that will benefit greatly from the operational resources and entrepreneurial spirit that we will provide. We have a clear path to grow this business organically and through add-on acquisitions.”

Luigi M. Chiaraviglio added: “We are excited to contribute to the growth of this niche leader, whose products are exported globally, into its next phase of development.”

“We brought together investors sharing our philosophy of long-term value creation,” stated Filippo Sciorilli Borrelli, Managing Director of Swiss Merchant Corporation. Borrelli went on to say, “We are eager to start this journey.”

Luigi M. Chiaraviglio and Renaud Delaage led the transaction. Filippo Sciorilli Borrelli led the equity syndication for Swiss Merchant Corporation and played a key role in the execution.

Omniplast has earned a strong reputation and a loyal customer base within the agricultural and greenhouse sector. The business produces and distributes pressure and non-pressure PVC piping systems for the transportation of gases and fluids. Within its diverse product portfolio, Omniplast has developed five quality standards from three-layer non-pressure pipes, to irrigation and KIWA pressure pipes, to pipe-related specialties. The business is supported by forward integrated logistical solutions enabling efficient packaging and transportation. Headquartered in Veghel, The Netherlands, Omniplast has approximately 60 employees.

OpenGate Capital acquired Omniplast through its legacy, pre-fund portfolio as one of three businesses within Ivy Group. At acquisition, Omniplast had two entities in The Netherlands and Germany, which were separated in 2018 as part of a strategy to maximize each entity’s value. The German business, which specializes in PVC pipes for the residential market, was not included in the transaction.

The realization of Omniplast follows OpenGate Capital’s announcement that NAKAN, another division within Ivy Group, had been sold to Westlake Chemical Corporation in January of 2019.

About OpenGate Capital

Founded in 2005, OpenGate Capital is a global private equity firm that strives to acquire and optimize lower middle market businesses throughout North American and Europe. With a strategic international presence and a focus on corporate carve-outs and complex situations, the firm’s expertise allows it to realize a seller’s divestiture objectives while mitigating the risks associated with a business’s transition to independence. OpenGate is headquartered in Los Angeles and Paris and has a seasoned in-house team of professionals overseeing the entire lifecycle of each investment. To learn more about OpenGate, please visit www.opengatecapital.com .

About Reedcapital

Reedcapital is a private investment firm focused on the acquisition, transformation and development of lower-middle-market businesses. The firm invests in both performing and underperforming companies to create long term sustainable value. Typical investment opportunities are corporate divestitures and carve-out, complex situations and underperforming businesses. Reedcapital and its partners have been involved in over 30 transactions ranging from corporate divestitures, turnaround acquisitions, industry consolidations and other special situations investments across a wide array of industries and geographical markets. More information available on www.reedcapital.fr .

About Luigi M. Chiaraviglio

Luigi has been a private equity investor for more than 15 years, with Compass Partners in London first and Investindustrial in Milan, Lugano and New York later and has completed over 10 transactions for a value in excess of Eur 2bn including buyouts or expansion capital deals, restructurings, refinancing and exits and has been on the board of several companies in Europe and the USA. He is the Managing Director of Vista Investors, an investment firm operating through a multi-family office model, focusing on repositioning and expanding lower mid-market businesses or corporate group divisions. For more information please visit www.vista-investors.com .

About Swiss Merchant Corporation SA

Swiss Merchant Corporation(“SMC”), founded in 1990, is a corporate finance advisory boutique based in Lugano, Switzerland. SMC specializes in offering tailor made services for its clients aimed at long-term value creation. SMC’s one-stop-shop approach is designed to fulfill clients’ needs. SMC started as a private equity firm, successfully managing four investment funds from 1989 until 2015. Whilst maintaining an active role in direct investments and club deals, SMC has leveraged its experience as an advisor to its portfolio companies to focus on helping clients make informed financial decisions. More information available on www.swissmerchantcorporation.ch .

Contact:

OpenGate Media Contacts Alanna Chaffin Email: achaffin@opengatecapital.com Telephone: +1 (310) 432-7000

Mike Sitrick Sitrick & Company Email: Mike_Sitrick@sitrick.com Telephone: +1 (310) 788-2850

OpenGate Business Development Contact Joshua Adams Email: jadams@opengatecapital.com Telephone: +1 (310) 432-7000

Reedcapital Media Contact Email: media@reedcapital.fr Telephone: +33 1 72 74 10 31

Luigi M. Chiaraviglio Media Contact Email: media@vista-investors.com Telephone: +41 79 95 95 795

Swiss Merchant Corporation Media Contact Email: info@swimeco.ch Telephone: +41 91 2103568

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye